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ABSTRACT
Introduction: Over 16 000 mastectomies are
performed in England and Wales annually. Acute
postoperative pain and nausea are common. The most
frequently occurring long-term complications are
chronic pain (up to 50%) and reduced shoulder
function (reported at 35%). Regional techniques that
improve acute postoperative pain relief may reduce the
incidence of these complications. This study assesses
the effectiveness of a 24-hour continuous local
anaesthetic in the subpectoral plane in improving
postoperative pain and quality of life in patients
undergoing mastectomy.
Methods and analysis: This is a randomised,
double blind, placebo-controlled, two-centre, parallel
group trial in women undergoing mastectomy with or
without axillary involvement. One hundred and sixty
participants will be randomised in a 1:1 ratio to receive
either 0.25% levobupivacaine or 0.9% saline by
subpectoral infusion postoperatively for 24 h. All
participants will be provided with an intravenous
morphine patient-controlled analgesia (PCA) system.
Participants will be followed-up for 24 h in hospital
and at approximately 14 days and 6 months
postoperatively. Joint primary outcome measures are
total morphine consumption and total pain score
(captured via patient-recorded visual analogue scale
(VAS) 4 hourly) during the first 24 h postoperatively.
Primary statistical analysis of total pain is based on the
area under the curve of pain versus time graph.
Secondary outcomes include PCA attempts in first
24 h; VAS pain scores and shoulder function by
goniometry at 24 h, 14 days (approximately) and
6 months; Verbal Rating Scale pain scores in first 24 h;
Brief Pain Inventory and Oxford Shoulder Score at
6 months; duration of hospital stay; incidence of
postoperative nausea and vomiting; cost-effectiveness.
Ethics and dissemination: The study is approved
by the South West England Research Ethics Committee
(12/SW/0149).
Results: will be published in a peer-reviewed journal
and presented at local, national and international
scientific meetings.
Trial registration: ISRCTN46621916. EudraCT 2011-
005775-16.
Strengths and limitations of this study
▪ This is a double-blind, randomised, placebo-
controlled trial.
▪ This is the first study to assess the use of a con-
tinuous local anaesthetic infusion in the subpec-
toral plane.
▪ This is the first study to assess the effects of
continuous local anaesthetic infusion on post-
operative shoulder function.
▪ The study includes an assessment of longer
term pain.
▪ All instruments for measuring postoperative pain,
including those used in this study, have limitations.
We have attempted to address this by using two
measures, morphine consumption and visual ana-
logue scale scores, as joint primary outcomes.
▪ Changing surgical practice means that fewer
simple mastectomies are being performed in
comparison with breast conservation (wide exci-
sion) surgery and skin-sparing mastectomy with
immediate reconstruction. This study does not
address whether any benefits demonstrated can
be extrapolated to these procedures.
▪ The study does not assess the effects of
surgeon variation or duration of surgery on pain
and recovery outcomes for patients.
▪ The study does not assess the level of sedation
in the postoperative period. Reduced sedation is
a potential benefit of reduced morphine
consumption.
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INTRODUCTION
In 2010, the lifetime risk in women of developing breast
cancer was estimated as one in eight, with the disease
now the most commonly occurring cancer in the UK.1
Surgery remains the treatment of choice, with around
43% of women with breast cancer opting for mastec-
tomy.2 A total of 16 595 mastectomies were performed in
England and Wales in 2012–2013.3 The most common
complications of mastectomy are postoperative acute and
chronic pain and slow recovery of shoulder function.
Acute pain in mastectomy patients is currently managed
with systemic opiates, either by intramuscular injection or
using an intravenous patient-controlled analgesia (PCA)
device. Chronic postoperative pain is frequent
(20–45%)4–7 and requires signiﬁcant use of National
Health Service (NHS) resources. Poor recovery of shoul-
der function, associated with initial poor analgesia,
impacts on quality of life long after the initial recovery
period.8 9 These effects are all the more signiﬁcant con-
sidering the young age at which many patients present.
Postoperative analgesia therefore remains a challenge
for these patients despite a range of treatment options.10
Most postoperative pain in mastectomy occurs within the
ﬁrst 24 h of surgery. Inadequately managed pain in the
acute postoperative phase is a major risk factor of
chronic pain syndromes,5 which are present in up to
50% of patients 6 months after operation.11 Impaired
shoulder function also causes signiﬁcant problems post-
mastectomy12–14 and it has been suggested that better
postoperative analgesia may enhance the effects of early
physiotherapy. There is no gold standard for pain relief
following mastectomy surgery.10 Morphine, the mainstay
of therapy, is associated with vomiting and excessive
drowsiness. Thoracic epidural and paravertebral blocks
have been shown to provide adequate analgesia,10 but
associated complications (eg, pneumothorax), although
rare, are severe and potentially life-threatening. Local
anaesthesia wound inﬁltration has not been adequately
studied using randomised controlled trials.10 An infor-
mal survey of current practice in the South West
Peninsula of England suggested that its use is patchy
and erratic, with a third of surgeons not using any at all
and others reporting a range of different methods of
administration and doses.
The use of wound catheters to deliver continuous local
anaesthetic has been shown to reduce postoperative pain
and analgesic requirements in cardiothoracic, ortho-
paedic and general surgery.6 15 16 The nerve supply to
the breast is predominantly from the lateral and anterior
branches of the second to sixth intercostal nerves and the
supraclavicular nerves.17 Nerves pass beneath the pec-
toral fascia before reaching the breast and it is here that
local anaesthetic may be deposited via a catheter, as a
bolus or subpectoral infusion. The ‘Pecs block’ was
described in 201118 as a technique for placing local
anaesthesia in the subpectoral plane at the time of
surgery. There have since been a number of similar
descriptions of ultrasound-guided chest wall local
anaesthetic techniques for use in breast surgery.19–21 Case
reports and small studies indicate that these techniques
are efﬁcacious in reducing postoperative pain, however
there are, as yet, no large randomised controlled trials.
So far these techniques have not been described with the
use of continuous local anaesthetic infusion.
Current published research relating to postmastect-
omy local anaesthesia infusion is scant. A meta-analysis
of surgically placed wound catheters concluded that
there was a trend towards improved analgesia in the
immediate post-operative period, however studies were
underpowered and often poorly designed.22 One rando-
mised study23 of 42 patients found no signiﬁcant differ-
ence in postoperative analgesia (as measured by PCA
use and pain scores) between administration of 4-hourly
20 mL bolus doses of 0.5% bupivacaine and placebo.
However, the technique tested involved inﬁltration via
wound drains which deposited local anaesthetic in a
more superﬁcial tissue plane than the subpectoral plane
and did not use a continuous infusion. Non-randomised,
non-blinded, retrospective and observational studies of
local anaesthetic infusion24–26 suggest more favourable
results. Baroody et al25 demonstrated a ﬁvefold reduction
in analgesic requirement following local anaesthetic
infusion after reconstructive breast surgery. Morrison
et al24 compared postoperative opioid use in mastectomy
patients receiving local anaesthetic infusion or no infu-
sion and found a signiﬁcant reduction in opiate use and
hospital length of stay in the local anaesthetic arm.
However, this was an unblinded retrospective analysis
and made no attempt to investigate chronic pain or arm
mobility. Lu et al26 compared local anaesthetic infusion
to placebo in patients undergoing reduction mammo-
plasty and reconstruction. Results showed reductions in
opiate use and pain scores in the local anaesthetic
group but controls were historical and the study was
unblinded and not randomised. Given the limitations of
the study designs, it is currently difﬁcult to make ﬁrm
conclusions or recommendations for clinical practice.
There are no published studies assessing the impact of
local anaesthetic inﬁltration on postoperative shoulder
function. There has recently been increased interest in
postoperative local anaesthesia for the reduction of
chronic pain. A 2012 Cochrane analysis pooled the
results of two trials and concluded that paravertebral
block may favour the reduction of chronic pain follow-
ing mastectomy in one in ﬁve patients.27
Levobupivacaine is the S(-)-isomer of bupivacaine. In
common with other local anaesthetic agents, it is widely
accepted that levobupivacaine blocks nerve conduction
in sensory and motor nerves by blocking voltage sensitive
sodium channels in the cell membrane. Levobupivacaine
exhibits fewer cardiovascular toxicity effects28 29 than
bupivacaine and, as such, is safer for use as an infusion.
There appears to be no measurable difference in clinical
effectiveness between the two agents.30
The aim of this study is to establish whether the use of
continuous local anaesthetic infusion in the subpectoral
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tissue plane can improve postoperative analgesia and
quality of life for patients undergoing mastectomy with
or without axillary surgery. If the use of this local anaes-
thetic infusion technique is shown to be more effective
than current practice, the reduction of pain and opiate
use in the immediate post-operative period would be a
signiﬁcant beneﬁt to patients. The technique also holds
the potential to improve patients’ quality of life by redu-
cing the longer term risks of chronic pain and impaired
shoulder function.
METHODS AND ANALYSIS
Study design
The study is a double blind, randomised, placebo-
controlled, two-centre, parallel group trial in 160 female
patients undergoing mastectomy with or without axillary
involvement. The study was originally designed as a
single centre study in Cornwall, but audit data prior to
the study start conﬁrmed a signiﬁcant reduction in the
number of mastectomies being conducted locally, follow-
ing changes in the surgical team and surgical practice.
In order to achieve the required sample size, the study
design was therefore amended to include two study sites.
At the same time, an emerging trend for early discharge
of patients postmastectomy prompted a change in the
timing of primary outcome data collection from 48 to
24 h postoperatively. These changes to the original study
design eventually delayed the study start by approxi-
mately 10 months.
Participants will be randomly allocated to receive
either 0.25% levobupivacaine or 0.9% sodium chloride
by subpectoral infusion postoperatively for 24 h. All par-
ticipants will be provided with an intravenous morphine
PCA system. Participants will be followed up for 24 h in
hospital and at approximately 14 days and 6 months
postoperatively as outpatients.
Setting and participants
The study is being conducted in breast surgery depart-
ments within two NHS Trusts in Cornwall and York,
England. The second site was selected after expressing
interest in the study and because of its similar mastec-
tomy pathway compared with the lead site. Eligible
patients comprise all women presenting for unilateral
mastectomy, with or without planned axillary clearance,
at one of the participating hospitals. Main exclusion cri-
teria are: primary reconstructive surgery; hypotension or
hypovolaemia; allergy or sensitivity to local anaesthetic
agents, morphine, paracetamol, ondansetron or cycli-
zine; daily opioid analgesic use; pregnancy. Study partici-
pants are patients who meet the screening criteria and
are willing and able to give informed consent.
Study recruitment
The recruitment process is designed to ﬁt in with
routine clinical practice. Potential participants are iden-
tiﬁed from those attending outpatient breast clinics for
discussion of breast cancer diagnosis and treatment
options. Surgery is usually scheduled within a month of
the initial clinic appointment, following attendance at a
preassessment clinic. Women attending clinic for discus-
sion of prophylactic mastectomy may also be eligible to
participate in the study.
Patients for whom mastectomy is a potential treatment
option and who appear eligible for the study are given a
brief verbal introduction to the study by a clinician or
nurse at the initial breast clinic consultation and pro-
vided with either a brief written study summary or a full
participant information sheet, as deemed appropriate.
Patients are subsequently telephoned within a few days
by the breast care nurse (or research nurse, depending
on local arrangements) and further information about
the study is provided verbally and/or by post to patients
who express further interest. Patients who are interested
in participating in the study are invited to meet the
research nurse at the routine preoperative assessment
clinic so that any further questions can be answered and
eligibility for the study conﬁrmed. Arrangements are
made for the patient to discuss aspects of the study with
the surgeon or anaesthetist if required. Written
informed consent is obtained from patients willing and
eligible to participate, by an appropriately trained
member of the research team. Patients who decline to
take part in the study are not obliged to give a reason
for declining but the reason(s) are recorded by the
research nurse if provided.
Study procedures
Figure 1 shows the participant pathway through the
study. Following informed consent, each participant is
assigned a unique study number. Baseline data are nor-
mally collected at the preoperative assessment clinic, fol-
lowing consent. At this point the research nurse brieﬂy
explains use of the morphine PCA system and famil-
iarises the participant with the Visual Analogue Scale
(VAS) pain scoring system. Each VAS score is recorded
on a separate page of a mini ﬂipchart. The participant
turns the page of the ﬂipchart after an entry is made, so
that the previous score is not visible for comparison
when the next score is recorded.
Interventions
The active investigational medicinal product is 0.25%
levobupivacaine (chirocaine), an established local anaes-
thetic infusion agent, prepared as a 2.5 mg/mL solution
and packaged by the manufacturer (Abbott) in
ampoules for injection. The comparator solution, 0.9%
sodium chloride, is sourced from standard NHS supplies
at the participating sites. Active and comparator trial
treatments are presented identically in infusion bags pre-
pared by the local hospital pharmacy prior to the oper-
ation date and supplied on an individual patient basis
according to treatment allocation. Bags are presented in
heat-sealed outer packaging and labelled in accordance
with current European Union regulatory requirements
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for clinical trials. Each bag is assigned a unique code
number and a 7-day expiry date.
Anaesthesia and surgery
Study participants receive a standardised anaesthetic
protocol with respect to analgesic and antiemetic medi-
cation (see online supplementary appendix 1).
Mastectomy is performed with/without sentinel lymph
node sampling or clearance, as clinically indicated.
Delivery of trial treatment
Trial treatment is delivered by means of an infusion cath-
eter and device, supplied as a sterile prepacked kit and
licensed for the delivery of local anaesthetic. At the end
of the surgical procedure the surgeon inserts the infusion
catheter percutaneously into the subpectoral plane
under direct vision within the surgical ﬁeld. After skin
closure, a 20 mL bolus of active or comparator treatment
is given via the catheter, which is then connected to the
infusion device to provide an infusion of trial treatment
at a continuous rate of 5 mL/h for 24 h. In the active
treatment arm this equates to a 50 mg bolus of levobupi-
vacaine followed by an infusion of 12.5 mg/h.
Postoperative management and outcome assessment
In the recovery unit, postoperative pain is routinely
managed with 2–3 mg aliquots of intravenous morphine
to achieve a Verbal Rating Scale pain score of none–
mild pain. All participants are provided with a PCA
system set up to deliver intravenous morphine boluses of
1 mg with a 5-minute lock-out and no background infu-
sion. Once all other routine recovery discharge criteria
have been met, the patient is transferred to the ward.
A baseline VAS pain score is recorded prior to transfer
to the ward.
Participants are asked to complete VAS pain scores at
rest every 4 h, with reminders from ward staff. The sub-
pectoral infusion is discontinued after 24 h and the cath-
eter removed, together with the PCA system. Outcome
measures are assessed at 24 h and at routine follow-up
visits, approximately 10–14 days and 6 months after the
day of surgery (table 1).
Primary outcome measures
The joint primary outcomes are (1) total morphine con-
sumption (mg) in the ﬁrst 24 h (deﬁned as the 24 h fol-
lowing start of the subpectoral infusion), including all
morphine given in the recovery unit and cumulative
Figure 1 Trial schematic.
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PCA use as recorded by the PCA device and (2) total
pain over the ﬁrst 24 h, as deﬁned by measurement of
the area-under-the-curve of each participant’s self-
reported pain scores at rest, measured using a VAS. VAS
pain scores are recorded in the recovery unit and then
at 4 hourly intervals for the ﬁrst 24 h. The VAS is pre-
sented as a 100 mm horizontal line with verbal anchors
at each end of ‘no pain’ and ‘worst pain possible’. The
study participant selects and marks with a pen the point
along the line that reﬂects their current pain percep-
tion. Periods of sleep are recorded retrospectively by the
participant.
Secondary outcome measures
Secondary outcome measures include the number of
PCA attempts in the ﬁrst 24 h following start of infusion;
VAS pain scores at rest at 24 h, 14 days and 6 months
after surgery; incidence of postoperative nausea and/or
vomiting and use of supplemental analgesics and post-
operative antiemetics in the ﬁrst 24 h; self-reported anal-
gesia use at 14 days and 6 months; duration of hospital
stay; shoulder movement assessed by goniometry at 24 h,
14 days and 6 months following surgery; Brief Pain
Inventory at 6 months; shoulder function (as measured
by the validated31) at 6 months. Items from the are also
assessed at the ﬁrst follow-up visit in relation to the previ-
ous 7 days. Following the participant’s discharge, the
length of stay in hospital is recorded by the research
nurse.
Randomisation
Patients who consent to participate and fulﬁl the eligibil-
ity criteria are randomly allocated to receive either levo-
bupivacaine or saline in a 1:1 ratio via a secure web-based
randomisation system. The allocation sequence is
computer-generated by the UKCRC-registered Peninsula
Clinical Trials Unit (CTU) in conjunction with an inde-
pendent statistician, using a random permuted block
design, with blocks of varying sizes. The block sizes will
not be disclosed, to ensure concealment. As post-
operative pain is expected to differ between patients who
are having simple mastectomy, mastectomy with sentinel
lymph node sampling or mastectomy with axillary node
clearance, randomisation is stratiﬁed by planned surgical
procedure and by recruiting centre. To ensure that the
study team, including the study statistician, remain blind
to participants’ allocated study groups, randomisation is
undertaken by the relevant hospital pharmacy
department.
Blinding and emergency unblinding
This is a double blind study and therefore participants,
the surgical/anaesthetic team and the research team are
unaware of each participant’s allocated treatment group.
To help assess the success of blinding, participants and
the research nurse completing the follow-up assessments
are asked to guess the participant’s treatment assign-
ment, at both the 14-day and 6-month follow-up visits.
In the event of a potential suspected unexpected
serious adverse reaction, unblinding will be undertaken
by the Sponsor in accordance with the regulatory
requirements for safety reporting in Clinical Trials of
Investigational Medicinal Products (CTIMPs).
Unblinding may also be performed at the request of a
senior clinician responsible for the care of a trial partici-
pant but such requests are likely to occur only in the
case of an adverse clinical event and are expected to be
rare. Any request to unblind treatment allocation for
Table 1 Trial schedule
Preoperative Postoperative
Baseline 24 h 14 days* 6 months
Screen/eligibility x OPERATION AND
SET-UP OF TRIAL INFUSIONConsent x
BMI x
Concomitant medication x x x
Oxford Shoulder Score (OSS) x x
Shoulder questions (from OSS) x
Shoulder goniometry x x x x
EQ-5D 5L x x x
Randomisation x
VAS pain score x x x
VRS pain score x
PCA attempts x
Total morphine consumption (oral/IV) x
Analgesia use x x x
Adverse events x x x
Brief Pain Inventory x
Service use x
*Approximately 10–14 days post-operatively according to local practice.
EQ-5D 5L, EuroQoL-5D 5L;VAS, Visual Analogue Scale; VRS, Verbal Rating Scale; PCA, patient-controlled analgesia.
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clinical reasons will be made directly to the relevant hos-
pital pharmacy and the treatment allocation will be
reported to the relevant clinician according to an
agreed procedure. The chief investigator and CTU trial
manager will be kept informed of all instances of
unblinding but remain blind to treatment allocations
themselves wherever possible. The pharmacy and CTU
will maintain a record of all requests for unblinding.
Data management
Data will be collected and stored in accordance with the
Data Protection Act, 1998. Data will be recorded on
study speciﬁc data collection forms and transferred to
the CTU for double-data entry on to a password-
protected database stored on a restricted access, secure
server. Participants’ anonymity will be maintained on all
documents. Direct access to the trial data will be
restricted to members of the research team and the
CTU, with access granted to the Sponsor on request.
All participants will be encouraged to continue with
follow-up as per protocol although they may withdraw
from the study at any time without it affecting their care.
Data collected prior to withdrawal will be included in
the study analysis unless a participant speciﬁcally
requests that their data are removed from the database.
Sample size
The study sample size was calculated to assess the joint
aims of the effectiveness of a 24-hour continuous sub-
pectoral local anaesthetic infusion on total morphine
consumption and total pain over the 24-hour postsur-
gery period. Few studies have addressed the question of
what reduction in total morphine use after breast
surgery might be clinically important. A small number
of studies have reported total morphine use after breast
surgery, at varying end points.32–39 Four have reported
total morphine use at 24 h postsurgery; three of these
were comparative studies. Two of these three studies
based their sample size calculations on the same prior
belief that the minimum clinically important difference
was 10 mg (estimated SD of 10 mg, estimated mean
24-hour total morphine consumption of 40 mg).38 39
Therefore, the minimum clinically important difference
in 24 h total morphine consumption was set as 10 mg.
These studies also showed actual SDs in 24 h post-
operative total morphine consumption of 10–22 mg. To
allow for the variability in the total morphine consump-
tion being at the upper end of this range, the sample
size calculation for total morphine consumption
assumed a SD of 20 mg. To detect a difference of 10 mg
between groups, with 80% power and at the 5% signiﬁ-
cance level, requires 65 participants per group.
Similarly, there is a lack of information on which to
base a formal sample size calculation for pain as the
( joint) primary outcome measure. With the sample size
of 65 participants per group, there will be approximately
80% power to detect an effect size of around 0.5 SDs on
the measure of pain. Such an effect size would be
considered as being of ‘moderate’ size.40 From studies
using a single VAS pain measure, it has been suggested
that clinically meaningful differences are of the magni-
tude of 20–30 mm on a 100 mm VAS,41 while a recent
review reported that at the group level the difference in
pain levels varied from 4 to 40 mm for acute pain.42
Assuming the SD of the VAS is between 1343 44 and
26 mm,37 45 this suggests that clinically meaningful effect
sizes are of the order of at least 0.8 SDs. To detect a dif-
ference of around 0.8 SDs would need 26 patients per
group, assuming a two-sided signiﬁcance level of 5%,
with 80% power. Therefore, the sample size of 65 partici-
pants per group will be large enough to detect clinically
relevant differences between groups, in terms of pain.
The primary outcome measures are at 24 h with a
minimal probability of drop out. However, enough parti-
cipants will be recruited to attempt to ensure 65 partici-
pants per group are followed up at 6 months. As patients
remain engaged with the breast service for clinical
reasons, loss to follow-up is also expected to be low but
there may be losses to the study because, for example, of
the need for further surgery. Therefore, in order to
achieve a study sample of 65 women per group at the
6-month follow-up, the aim is to recruit a total of 160
participants over a 2-year period, which allows for a loss
to follow-up rate of just under 20%.
Statistical analyses
The primary analyses are all prespeciﬁed and a detailed
statistical analysis plan will be completed and agreed by
the Data Monitoring Committee (DMC) prior to start of
analyses. Data will be reported and presented according
to the CONSORT statement.46 Ninety-ﬁve per cent CIs
will be calculated and presented where possible. The
trial statistician will be presented with a database by the
CTU containing a group code for each participant but
not identifying which group is which; only after ﬁnal
analysis will the individual groups be identiﬁed.
The primary statistical analysis will follow an intention-
to-treat approach, with the intent-to-treat population
deﬁned as all trial participants who completed the base-
line assessment and underwent surgery. A per protocol
analysis may be undertaken as a sensitivity analysis. The
analysis of adverse events will be presented on a per
protocol basis.
The primary analysis will compare (1) total morphine
consumption and (2) 24-h pain AUC at 24 h postsurgery
between the two groups using an analysis of covariance,
including the stratiﬁcation factors as covariates, with suit-
able transformation of total morphine consumption and
pain AUC considered as necessary. The estimates of the
differences in mean total morphine consumption and
mean pain AUC will be presented, together with a 95% CI
for the difference. Secondary outcomes will be compared
between groups in a similar way using analysis of covari-
ance for continuous outcomes and logistic regression for
binary outcomes such as incidence of postoperative
nausea and/or vomiting and use of postoperative
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antiemetics in the 24 h following surgery. Comparisons of
interest will be presented with 95% CIs.
Interim analysis
An interim analysis will be undertaken after the 14-day
follow-up data have been collected for the ﬁrst 80 parti-
cipants recruited. Given the nature of the study a strin-
gent criterion has been set for early termination of the
trial on grounds of efﬁcacy, namely p<0.001 for both the
primary outcomes, else continuation of the trial being
recommended. Other outcomes to be included in the
interim analysis will be agreed with the DMC but are
likely to include pain and vomiting, as well as 6-month
outcomes data available at the time of the interim ana-
lysis. The interim analysis will not inﬂuence the ﬁnal
statistical analyses; given the single interim analysis and
the stringent stopping criteria, any further adjustment is
not considered to be necessary. Serious adverse events
(SAEs) will be routinely reported to the DMC and dis-
cussed (by email/telephone) as considered necessary;
they will be formally reviewed at the interim analysis
within the context of any emerging evidence on efﬁcacy.
Missing data
The nature of missing data will be examined to consider
appropriate approaches such as multiple imputation.
Where assumptions are necessarily made, alternative
assumptions will also be used to conduct additional ana-
lyses examining how sensitive the results are to the base-
line assumptions. For the joint primary outcome of pain
VAS, the AUC can be calculated from available VAS
scores even if some are missing, by using linear interpol-
ation; but if one or more observations are missing at the
end of the 24-h period, the last observation recorded
will be carried forward in the primary analysis.
Economic evaluation
The study will include an economic evaluation from an
NHS perspective. Following the National Institute for
Health and Care Excellence (NICE) reference case, the
primary outcome for the economic evaluation will be
the incremental cost per quality-adjusted life-year
(QALY) gained. The study will collect resource use data
for the main drivers of the marginal cost. Unit costs will
be assessed using standard NHS reference costs and
prices. Health-related quality of life will be measured
using the EuroQoL-5D (EQ5D)-5L data collected at
baseline, 14 days and 6 months and valued using the
interim ‘crosswalk’ value set.47 QALYs will be estimated
within trial by assuming a constant tariff value for days
0–14 and a straight line extrapolation between tariff
scores at 14 days and 6 months.
The outcome of the economic evaluation will be the
incremental cost-effectiveness ratio (ICER; the add-
itional cost per QALY gained). Sampling variation for
the ICER will be reported as the SD, estimated by boot-
strapping and illustrated on the cost-effectiveness plane.
Sensitivity analysis will be undertaken as appropriate
(depending on sampling variation and an analysis of
relationships between QALY estimates and the other
outcome measures) but it will include an analysis of the
sensitivity of the estimated ICER to the functional form
of the extrapolation between tariff scores at 14 days and
6 months.
Ethics and dissemination
Ethical and safety considerations
Postoperatively, all participants are provided with a mor-
phine PCA system in addition to the subpectoral infu-
sion of trial treatment and therefore it is not considered
that there are any ethical issues in using a placebo
control. The recommended maximum single dose of
levobupivacaine is 150 mg. The dose for postoperative
pain management should not exceed 18.75 mg/h and
the maximum recommended dose during a 24-h period
is 400 mg. The maximum 24-h dose in this study is
350 mg which is therefore well within recognised safe
limits.
Research governance
The protocol has been approved by the South West—
Central Bristol Research Ethics Committee (REC refer-
ence 12/SW/0149) and follows the recent SPIRIT guide-
lines.48 The Sponsor is responsible for judging the
substantiality of any amendments to the study protocol.
Important protocol modiﬁcations will be communicated
to relevant parties by the Peninsula Clinical Trials Unit.
The study is conducted subject to the terms of a
Clinical Trial Authorisation issued by the Medicines and
Healthcare products Regulatory Agency (MHRA) and in
compliance with the principles of the Declaration of
Helsinki, ICH GCP, the Data Protection Act 1988 and
the Medicines for Human Use (Clinical Trials)
Regulations 2004 and subsequent amendments. The
study has been adopted by the NIHR Clinical Research
Network and has relevant local NHS Research and
Development approvals. The study is sponsored by Royal
Cornwall Hospitals NHS Trust and managed by the
UKCRC-registered Peninsula Clinical Trials Unit at
Plymouth University (Registration No.31).
A Trial Management Team meets regularly to monitor
and discuss the progress of the trial and to address any
issues that arise. A Trial Steering Committee (TSC), with
an independent chair, meets approximately every
6–9 months to oversee the overall conduct of the trial.
A Data Monitoring Committee (DMC), comprising two
independent clinicians and one independent statistician,
meets approximately every 9–12 months to monitor
safety and ethics, including issues relating to attrition,
overall data completeness and patient safety. The agreed
role and responsibilities of both committees are set out
in written charters and the DMC provides written recom-
mendations to the TSC following each meeting. The
CTU will conduct central and site monitoring in accord-
ance with a risk-based monitoring plan and the study
Sponsor may audit trial conduct as deemed appropriate.
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Timelines and dissemination plans
The study start was delayed due to amendments to the
study design, described earlier. Research Ethics
Committee approval was obtained in June 2012.
Recruitment and training of staff involved in the study
started in autumn 2012, and participant recruitment
started at the ﬁrst study site in December 2012.
Participant recruitment is due to be completed by the
end of 2014, with the ﬁnal 6-month follow-up visits in
early summer 2015. Statistical analyses will start once
ﬁnal data collection, monitoring and data cleaning is
complete. The chief investigator will establish a writing
committee comprising individuals who have made key
contributions to study design and conduct and it is
anticipated that the ﬁrst publications will be ready for
submission by early 2016. As well as the submission of
research articles to appropriate peer-reviewed journals,
research ﬁndings will be submitted for presentation at
local, national and international scientiﬁc meetings
including the European Society of Regional Anaesthesia
annual scientiﬁc meeting.
The study team will prepare a plain English summary
of the study results which will be sent to the study parti-
cipants as soon as possible after the end of the trial. In
addition, the ﬁnal results of the study will be presented
at meetings of the local breast cancer support groups.
CONCLUSIONS
The lack of good quality evidence regarding the effect-
iveness of a continuous local anaesthetic infusion on
postoperative pain following mastectomy indicates the
need for well-designed clinical trials to investigate this
subject. This study has been designed to investigate
whether the use of a continuous local anaesthetic infu-
sion in the subpectoral tissue plane can improve post-
operative analgesia and quality of life for patients
undergoing mastectomy, with or without axillary surgery.
This is the ﬁrst study to assess the use of such a con-
tinuous infusion in the subpectoral plane, as well as the
ﬁrst study to assess the effects on postoperative shoulder
function or the development of chronic pain and will
therefore give a pragmatic answer to the question of
whether continuous local anaesthetic infusion in the
subpectoral tissue plane should be used in these
patients.
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